Barclays’s Acura Pharmaceuticals ACUR Stock Holding History

Barclays’s Portfolio ACUR Stock Details ACUR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	–	Sell	-1,782	Closed	–	–	7820
2014 Q3	$0	Hold	1,782	–	–	﹤0.01%	7962
2014 Q2	$9K	Hold	1,782	–	–	﹤0.01%	6906
2014 Q1	$9K	Hold	1,782	–	–	﹤0.01%	6994
2013 Q4	$9K	Hold	1,782	–	–	﹤0.01%	7042
2013 Q3	$9K	Sell	1,782 -5,592	-76%	-$49.4K	﹤0.01%	6838
2013 Q2	$69K	Buy	+7,374	New	+$83.3K	﹤0.01%	6079

Other funds holding ACUR

EWM

Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

RIL

Rothschild Investment LLC Chicago, Illinois $1.91B AUM 24.37% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

FWP

FAS Wealth Partners Leawood, Kansas $1.61B AUM 19.97% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Barclays's ACUR Position: Q4 2014 in Review

Barclays sold out of Acura Pharmaceuticals (ACUR) in Q4 2014, closing a stake of 1,782 shares.

Barclays first reported a position in ACUR in Q2 2013 and held it in 6 quarters. The position peaked at $69K in Q2 2013. 33 funds tracked by Wall St. Rank hold ACUR as of Q4 2014.

Barclays reported no remaining Acura Pharmaceuticals position as of Q4 2014 after selling out during the quarter.
Barclays sold 1,782 Acura Pharmaceuticals shares in Q4 2014.
Barclays first reported a position in Acura Pharmaceuticals in Q2 2013 and held it in 6 quarters.
Barclays's Acura Pharmaceuticals position peaked at $69K in Q2 2013.
33 funds tracked by Wall St. Rank held Acura Pharmaceuticals as of Q4 2014.

Based on Barclays's 13F filing for Q4 2014, filed 13 Feb 2015.